Search and analyze individual stocks with comprehensive metrics

Divis Laboratories Ltd

DIVISLABPharmaceuticals
6236.00+0.00 (+0.00%)
As on 16 Jan 2026, 10:14 amMarket Closed

Fundamental Score

...

Divis Laboratories Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Average

Return on Equity

15.35%
Excellent

Return on Capital Employed

20.44%
Excellent

Operating Profit Margin (5Y)

34.98%
Poor

Dividend Yield

0.47%

Valuation Metrics

Poor

Price to Earnings

68.59x

Market Capitalization

1.70L (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

35.10%
Average

YoY Quarterly Sales Growth

16.12%
Good

Sales Growth (5Y)

11.65%
Average

EPS Growth (5Y)

10.41%
Average

Profit Growth (5Y)

10.41%

Financial Health

Excellent

Debt to Equity

0.01x
Excellent

Interest Coverage

270.58x
Excellent

Free Cash Flow (5Y)

4.70K (Cr)

Ownership Structure

Good

Promoter Holding

51.89%
Good

FII Holding

19.39%
Good

DII Holding

19.68%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.
51.89%
Promoter Holding
1.70L (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of DIVISLAB across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (15.35%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (20.44%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (34.98%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Robust Profit Growth (35.10%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (16.12%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (270.58x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Cash Generation (₹4695.21 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (51.89%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Strong Institutional Confidence (FII+DII: 39.07%)

Observation: Significant professional investor participation indicates quality recognition.

Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 68.59x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Divis Laboratories Ltd

About DIVISLAB

Business Overview

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Company Details

Symbol:DIVISLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
CEO & Whole-Time Director
Mr. Venkata Ramana Nimmagadda B.Sc.(Chem)
Executive Director
Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D.
MD & Executive Director

Corporate Events

Upcoming
Earnings Date
2026-02-02
Recent
Ex-Dividend Date
2025-07-25

DIVISLAB Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)15.35%
Return on Capital Employed20.44%
Operating Profit Margin (5Y)34.98%
Debt to Equity Ratio0.01
Interest Coverage Ratio270.58

Growth & Valuation

Sales Growth (5Y)11.65%
Profit Growth (5Y)10.41%
EPS Growth (5Y)10.41%
YoY Quarterly Profit Growth35.10%
YoY Quarterly Sales Growth16.12%

Frequently Asked Questions

What is the current price of Divis Laboratories Ltd (DIVISLAB)?

As of 16 Jan 2026, 10:14 am IST, Divis Laboratories Ltd (DIVISLAB) is currently trading at ₹6236.00. The stock has a market capitalization of ₹1.70L (Cr).

Is DIVISLAB share price Overvalued or Undervalued?

DIVISLAB is currently trading at a P/E ratio of 68.59x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Divis Laboratories Ltd share price?

Key factors influencing DIVISLAB's price include its quarterly earnings growth (Sales Growth: 16.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Divis Laboratories Ltd a good stock for long-term investment?

Divis Laboratories Ltd shows a 5-year Profit Growth of 10.41% and an ROE of 15.35%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing.

How does Divis Laboratories Ltd compare with its industry peers?

Divis Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare DIVISLAB's P/E of 68.59x and ROE of 15.35% against the industry averages to determine its competitive standing.

What is the P/E ratio of DIVISLAB and what does it mean?

DIVISLAB has a P/E ratio of 68.59x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹69 for every ₹1 of annual earnings.

How is DIVISLAB performing according to Bull Run's analysis?

DIVISLAB has a Bull Run fundamental score of 67.9/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does DIVISLAB belong to?

DIVISLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Divis Laboratories Ltd.

What is Return on Equity (ROE) and why is it important for DIVISLAB?

DIVISLAB has an ROE of 15.35%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Divis Laboratories Ltd generates profits from shareholders' equity.

How is DIVISLAB's debt-to-equity ratio and what does it indicate?

DIVISLAB has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is DIVISLAB's dividend yield and is it a good dividend stock?

DIVISLAB offers a dividend yield of 0.47%, which means you receive ₹0.47 annual dividend for every ₹100 invested.

How has DIVISLAB grown over the past 5 years?

DIVISLAB has achieved 5-year growth rates of: Sales Growth 11.65%, Profit Growth 10.41%, and EPS Growth 10.41%.

What is the promoter holding in DIVISLAB and why does it matter?

Promoters hold 51.89% of DIVISLAB shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is DIVISLAB's market capitalization category?

DIVISLAB has a market capitalization of ₹170446 crores, placing it in the Large-cap category.

How volatile is DIVISLAB stock?

DIVISLAB has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for DIVISLAB?

DIVISLAB has a 52-week high of ₹N/A and low of ₹N/A.

What is DIVISLAB's operating profit margin trend?

DIVISLAB has a 5-year average Operating Profit Margin (OPM) of 34.98%, indicating the company's operational efficiency.

How is DIVISLAB's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 16.12% and YoY Profit Growth of 35.10%.

What is the institutional holding pattern in DIVISLAB?

DIVISLAB has FII holding of 19.39% and DII holding of 19.68%. Significant institutional holding often suggests professional confidence in the stock.